Serum C-reactive protein metabolite (CRPM) is associated with incidence of contralateral knee osteoarthritis

Autor: Jeppe Ragnar Andersen, M. Michaelis, Asger Reinstrup Bihlet, Claus Christiansen, Inger Byrjalsen, Bente Juhl Riis, Christoph Ladel, Anne-Christine Bay-Jensen, Morten A. Karsdal, Hans Guehring
Rok vydání: 2020
Předmět:
Male
Metabolite
Osteoarthritis
Gastroenterology
Arthritis
Rheumatoid

Cohort Studies
Immunological techniques
chemistry.chemical_compound
0302 clinical medicine
Odds Ratio
030212 general & internal medicine
Analytical biochemistry
Multidisciplinary
biology
Incidence (epidemiology)
Incidence
Biological techniques
Proteases
Middle Aged
Osteoarthritis
Knee

C-Reactive Protein
Rheumatoid arthritis
Enzyme mechanisms
Biomarker (medicine)
Medicine
Female
Disease Susceptibility
medicine.symptom
Oligopeptides
Biotechnology
Adult
medicine.medical_specialty
Science
Immunology
Inflammation
Article
03 medical and health sciences
Rheumatology
Internal medicine
medicine
Humans
Aged
030203 arthritis & rheumatology
business.industry
C-reactive protein
Proteins
Odds ratio
medicine.disease
chemistry
ROC Curve
biology.protein
business
Biomarkers
Zdroj: Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
ISSN: 2045-2322
Popis: The heterogeneous nature of osteoarthritis (OA) and the need to subtype patients is widely accepted in the field. The biomarker CRPM, a metabolite of C-reactive protein (CRP), is released to the circulation during inflammation. Blood CRPM levels have shown to be associated with disease activity and response to treatment in rheumatoid arthritis (RA). We investigated the level of blood CRPM in OA compared to RA using data from two phase III knee OA and two RA studies (N = 1591). Moreover, the association between CRPM levels and radiographic progression was investigated. The mean CRPM levels were significantly lower in OA (8.5 [95% CI 8.3–8.8] ng/mL, n = 781) compared to the RA patients (12.8 [9.5–16.0] ng/mL, n = 60); however, a significant subset of OA patients (31%) had CRPM levels (≥ 9 ng/mL) comparable to RA. Furthermore, OA patients (n = 152) with CRPM levels ≥ 9 ng/mL were more likely to develop contra-lateral knee OA assessed by X-ray over a two-year follow-up period with an odds ratio of 2.2 [1.0–4.7]. These data suggest that CRPM is a blood-based biochemical marker for early identification OA patients with an inflammatory phenotype.
Databáze: OpenAIRE